Log in

NASDAQ:CKPT - Checkpoint Therapeutics Stock Price, Forecast & News

$1.26
+0.05 (+4.13 %)
(As of 12/9/2019 04:54 AM ET)
Today's Range
$1.22
Now: $1.26
$1.27
50-Day Range
$1.20
MA: $1.68
$2.09
52-Week Range
$1.15
Now: $1.26
$5.20
Volume149,676 shs
Average Volume290,463 shs
Market Capitalization$48.16 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59
Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.51 million
Book Value$0.42 per share

Profitability

Net Income$-36,370,000.00
Net Margins-583.52%

Miscellaneous

Employees7
Market Cap$48.16 million
Next Earnings Date3/20/2020 (Estimated)
OptionableNot Optionable

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.


Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.02. The firm had revenue of $0.28 million for the quarter, compared to analysts' expectations of $0.70 million. Checkpoint Therapeutics had a negative return on equity of 339.99% and a negative net margin of 583.52%. View Checkpoint Therapeutics' Earnings History.

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Checkpoint Therapeutics.

What price target have analysts set for CKPT?

2 analysts have issued twelve-month price objectives for Checkpoint Therapeutics' stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Checkpoint Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 1,090.5% from the stock's current price. View Analyst Price Targets for Checkpoint Therapeutics.

What is the consensus analysts' recommendation for Checkpoint Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Checkpoint Therapeutics.

What are Wall Street analysts saying about Checkpoint Therapeutics stock?

Here are some recent quotes from research analysts about Checkpoint Therapeutics stock:
  • 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, cosibelimab and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (8/9/2019)
  • 2. According to Zacks Investment Research, "Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. " (3/20/2019)

Has Checkpoint Therapeutics been receiving favorable news coverage?

News stories about CKPT stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Checkpoint Therapeutics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Checkpoint Therapeutics.

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include PTC Therapeutics (PTCT), TG Therapeutics (TGTX), Synergy Pharmaceuticals (SGYP), Viking Therapeutics (VKTX), Avid Bioservices (CDMO), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Verastem (VSTM) and Baidu (BIDU).

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the folowing people:
  • Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (0.88%), Park Avenue Securities LLC (0.14%), Squarepoint Ops LLC (0.05%) and BB&T Securities LLC (0.03%). View Institutional Ownership Trends for Checkpoint Therapeutics.

Which major investors are buying Checkpoint Therapeutics stock?

CKPT stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Park Avenue Securities LLC, Squarepoint Ops LLC and BB&T Securities LLC. View Insider Buying and Selling for Checkpoint Therapeutics.

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $1.26.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $48.16 million and generates $3.51 million in revenue each year. The company earns $-36,370,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.View Additional Information About Checkpoint Therapeutics.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is http://www.checkpointtx.com/.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  147 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  272
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel